Capricor Therapeutics Completes Submission Of Biologics License Application To The U.S. FDA For Deramiocel
T-Reuters
01-02
Capricor Therapeutics Inc:Capricor Therapeutics Completes Submission Of Biologics License Application To The U.S. Fda For Deramiocel For The Treatment Of Duchenne Muscular Dystrophy.Capricor Therapeutics - Bla Submission Triggers $10 Million Milestone Payment To Capricor From Nippon Shinyaku.